All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Please provide your email address to receive an email when new articles are posted on . The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Could Zoltux's Instant Solar Kit Be the Answer to Hassle-Free Solar Power? My Favorite Ina Garten Recipe Is So Lazy, It's Brilliant Against the odds, Prince Harry has won a landmark victory ...

Merck & Co Inc (NYSE:MRK) recently received regulatory approval for Winrevair (sotatercept), a groundbreaking therapy for adults with pulmonary arterial hypertension (PAH). This approval marks a ...

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

Publication on Dec. 12, 2024, of data analysis regarding Merck & Co. Inc.’s Winrevair (sotatercept) in Clinical Pharmacology & Therapeutics may have put investors in mind of the odds for the activin ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...